Jove
Visualize
Contact Us

Related Concept Videos

Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

43
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
43
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

57
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
57
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

43
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
43
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

32
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
32
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.0K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

27
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
27

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review.

International forum of allergy & rhinology·2026
Same author

Sleep disturbances in patients with vasculitis.

Sleep medicine·2026
Same author

Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.

EULAR rheumatology open·2026
Same author

IgG4-related disease presenting as an omental mass.

BMJ case reports·2026
Same author

Thromboembolic events in giant cell arteritis: a scoping review.

Annals of medicine and surgery (2012)·2026
Same author

Correction: Comprehensive immune profiling identifies alterations in adaptive and innate immune responses in granulomatosis with polyangiitis patients in remission.

Frontiers in immunology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 3, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K

Updates in ANCA-associated vasculitis.

Carolyn Ross1, Jean-Paul Makhzoum2, Christian Pagnoux1

  • 1Division of Rheumatology, Department of Medicine, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Ontario, Canada.

European Journal of Rheumatology
|February 14, 2022
PubMed
Summary

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) research reveals complex immune dysregulation. New therapies like avacopan offer promising, potentially steroid-free treatment options for ANCA-associated vasculitis.

More Related Videos

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K

Related Experiment Videos

Last Updated: Oct 3, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K

Area of Science:

  • Immunology
  • Rheumatology
  • Nephrology

Background:

  • Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are rare small-vessel autoimmune diseases.
  • Pathogenesis involves immune dysregulation, genetic, and environmental factors.
  • ANCA-associated vasculitides include granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.

Purpose of the Study:

  • To review recent advancements in understanding AAV pathogenesis.
  • To discuss evolving therapeutic strategies for AAV management.
  • To highlight the potential of novel agents like avacopan.

Main Methods:

  • Review of recent research, including genome-wide association studies.
  • Analysis of clinical trial data for therapeutic regimens.
  • Examination of pathogenic roles of immune cells and complement pathways.

Main Results:

  • Genetic predispositions identified, particularly in the major histocompatibility complex region.
  • Antimyeloperoxidase ANCA (MPO-ANCA) pathogenic role supported by animal models.
  • Avacopan shows promising results in clinical studies for AAV.
  • Reduced-dose glucocorticoids are effective with fewer side effects.
  • Rituximab demonstrates superiority over older agents for maintenance therapy.

Conclusions:

  • AAV pathogenesis is multifactorial, involving genetic susceptibility and immune system dysregulation.
  • Therapeutic landscape for AAV is rapidly evolving with new agents and refined protocols.
  • Avacopan and optimized rituximab use represent significant progress in AAV treatment.
  • Future research directions include defining optimal maintenance strategies and exploring novel therapies.